<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567814</url>
  </required_header>
  <id_info>
    <org_study_id>ECA-001</org_study_id>
    <nct_id>NCT00567814</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Embera NeuroTherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Embera NeuroTherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be randomly assigned to receive either one of the two potential dose
      combinations of the study medications or placebo over 6 weeks. The study will include twice
      weekly visits to the research clinic for laboratory studies, safety assessments and urine
      drug screens. Subjects will also be questioned regarding drug craving and mood symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction or elimination of cocaine craving as evidenced by the Cocaine Craving Questionnaire</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction or elimination of cocaine use as evidenced by self-report and urine toxicology</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in anxiety and depression symptoms</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Cocaine Addiction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lower dose combination of metyrapone with oxazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Higher dose combination of metyrapone with oxazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metyrapone</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Metopirone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxazepam</intervention_name>
    <description>Twice Daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Serax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 - 50 years of age

          -  Requests treatment for cocaine addiction

          -  Meets the DSM-IV criteria for cocaine dependency

          -  Able to provide written informed consent and comply with the study

          -  Females of childbearing potential must have a negative pregnancy test and must be
             using adequate birth control during the study

          -  Test positive for cocaine on a urinary drug screen

          -  Healthy and medically stable in the opinion of the Principal Investigator

        Exclusion Criteria:

          -  Liver enzymes greater than two times normal

          -  Any history of hepatitis

          -  History of disorders requiring chronic treatment with steroids

          -  Significantly abnormal ECG

          -  Any prominent DSM-IV axis I disorders other than cocaine dependence

          -  Any subject who presents as a danger to self or others in the opinion of the Principal
             Investigator

          -  Concomitant use of methamphetamine as determined by self-reporting and verified by
             measurement of methamphetamine in urinary drug screen

          -  Alcohol consumption greater than 4 drinks per day (1 Drink = 12 oz beer; 5 oz wine;
             1.5 oz shot of liquor)

          -  Any clinically significant laboratory test abnormalities

          -  Use of any concomitant medication during the study that would interfere with study
             medications

          -  Serum cortisol less than 3 Âµg/dl at any time before or during study

          -  Treatment with an investigational product within 30 days prior to study enrollment

          -  Currently seeking other forms of professional addiction treatment

          -  Known allergic reaction to oxazepam or metyrapone

          -  Lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita S Kablinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSU Health Sciences Center - Shreveport</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Psychopharmacology Research Clinic</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <last_update_submitted>December 30, 2008</last_update_submitted>
  <last_update_submitted_qc>December 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Marie Lindner, MD/Medical Monitor</name_title>
    <organization>Embera NeuroTherapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Dependence</keyword>
  <keyword>Addiction</keyword>
  <keyword>Cortisol</keyword>
  <keyword>GABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Oxazepam</mesh_term>
    <mesh_term>Metyrapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

